Keros Therapeutics(KROS) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results LEXINGTON, Mass., May 8, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a busi ...